Back to ADXS Stock Lookup

Advaxis (ADXS) – Company Press Releases

Sep 10, 2021 08:30 AM Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
Aug 11, 2021 08:00 AM Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.
Jul 15, 2021 08:00 AM Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Jul 14, 2021 04:01 PM Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
Jul 7, 2021 02:18 PM ADVAXIS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADXS and Encourages Investors to Contact the Firm
Jul 6, 2021 06:00 AM Advaxis and Biosight Announce Entry into Definitive Merger Agreement
Jun 14, 2021 04:05 PM Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
May 19, 2021 05:01 PM Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 28, 2021 04:30 PM Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 26, 2021 11:07 AM UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies
Apr 26, 2021 08:00 AM Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
Apr 12, 2021 08:30 AM Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Apr 10, 2021 08:31 AM Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
Apr 5, 2021 08:00 AM Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
Apr 2, 2021 07:33 AM Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director
Mar 23, 2021 11:33 AM Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
Mar 16, 2021 09:00 AM Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
Mar 12, 2021 08:00 AM Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Jan 25, 2021 07:00 AM Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
Jan 19, 2021 08:00 AM Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
Dec 22, 2020 01:42 PM Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Nov 27, 2020 12:07 PM Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
Nov 24, 2020 08:30 AM Advaxis, Inc. Announces Pricing of $8 Million Public Offering
Nov 23, 2020 04:05 PM Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Nov 9, 2020 08:01 AM Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 26, 2020 08:00 AM Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
Oct 15, 2020 08:00 AM Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
Sep 29, 2020 08:30 AM Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
Sep 24, 2020 08:00 AM Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
Sep 10, 2020 08:00 AM Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update
Sep 4, 2020 04:30 PM Advaxis Announces Resignation of Chief Financial Officer
Aug 27, 2020 08:00 AM Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference
Aug 3, 2020 08:00 AM Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
Jun 23, 2020 08:00 AM Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners
Jun 11, 2020 08:00 AM Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
Jun 1, 2020 08:00 AM Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020
May 14, 2020 08:00 AM Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
Mar 13, 2020 09:00 AM Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update
Mar 3, 2020 04:01 PM Advaxis to Present at the 2020 LD Micro Virtual Conference
Feb 27, 2020 09:00 AM Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference
Feb 20, 2020 08:00 AM Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
Feb 13, 2020 08:00 AM Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
Feb 11, 2020 01:00 PM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Feb 11, 2020 08:00 AM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Jan 30, 2020 09:23 AM Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
Jan 21, 2020 08:30 AM Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering
Jan 7, 2020 08:00 AM Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
Dec 20, 2019 08:00 AM Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
Dec 4, 2019 08:00 AM Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference
Dec 3, 2019 08:00 AM Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer

Back to ADXS Stock Lookup